Incentive Spirometry in Routine Management of COPD Patients

December 23, 2022 updated by: Amal A. El-Koa, Menoufia University

Value of Incentive Spirometry in Routine Management of COPD Patients and Its Effect on Diaphragmatic Function

The incentive spirometer is a device that encourages patients, with visual and other positive feedback, to maximally inflate their lungs and sustain that inflation. However, its efficacy in patients with COPD has been little documented especially in diaphragmatic function. This study tried to assess the role of incentive spirometry on Spirometric functions, Sonographic diaphragmatic function, and the scale of dyspnea in COPD patients with exacerbation and with follow-up of these parameters after 2 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Forty COPD patients were admitted with an acute exacerbation and the patients were divided randomly into 2 equal groups: the first used the incentive spirometer together with medical treatment (according to GOLD guidelines) for 2 months and the second received only medical treatment for 2 months. All participants, on admission, underwent assessment of mMRC dyspnea scale, spirometry, arterial blood gases, and diaphragmatic ultrasound. Then, a follow-up of the participants was done after 2 months with the same parameters and a comparison between both groups was done.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • Amal A. El-Koa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • confirmed cases of COPD according to the criteria GOLD
  • age more than 40 years

Exclusion Criteria:

  • bad acoustic window by ultrasound
  • other chronic respiratory diseases
  • lung malignancy
  • recent major surgery
  • inability to complete or perform the study
  • patient refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group 1
participants would use incentive spirometry for 2 months together with ordinary medical treatment
It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
No Intervention: group 2
participants would receive only ordinary medical treatment for 2 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
assessing the change in baseline diaphragmatic excursion in cm
Time Frame: 2 months
assessing the change from Baseline diaphragmatic excursion (in cm) using ultrasound to 2 months
2 months
assessing the change in baseline percentage of diaphragmatic thickness fraction
Time Frame: 2 months
assessing the change from baseline percentage of diaphragmatic thickness fraction (%) using ultrasound to 2 months
2 months
assessing the change in baseline forced vital capacity percentage of predicted
Time Frame: 2 months
assessing the change from baseline forced vital capacity percentage of predicted (%) using spirometry to 2 months
2 months
assessing the change in baseline forced expiratory volume in 1st second/forced vital capacity percentage (%)
Time Frame: 2 months
assessing the change from baseline forced expiratory volume in 1st second/forced vital capacity percentage (%) using spirometry to 2 months
2 months
assessing the change in baseline peak expiratory flow rate percentage
Time Frame: 2 months
assessing the change from baseline peak expiratory flow rate percentage (%) using spirometry to 2 months
2 months
change in arterial blood gases
Time Frame: 2 months
assessment the change in baseline PaO2 and PaCO2 (in mmHg) to 2 months
2 months
assessing the change in mMRC dysnea scale
Time Frame: 2 months
assessing the change in the severity of dyspnea by mMRC dysnea scale from baseline to 2 months. It is 5 statements giving grades from 0 to 4 with the higher the degree, the more severe the shortness of breath in patients with COPD
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2021

Primary Completion (Actual)

May 1, 2022

Study Completion (Actual)

July 1, 2022

Study Registration Dates

First Submitted

December 16, 2022

First Submitted That Met QC Criteria

December 23, 2022

First Posted (Estimate)

January 11, 2023

Study Record Updates

Last Update Posted (Estimate)

January 11, 2023

Last Update Submitted That Met QC Criteria

December 23, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 6/2022CHES4-1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on incentive spirometry

3
Subscribe